|
|
|
|
GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males
GARDASIL[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV)...
|
|
|
Preventive measures are still the best strategy Aspiration syndromes: Pneumonia and pneumonitis key words: Asp
abstract: While the risk factors for aspiration pneumonia are similar to those for aspiration pneumonitis, the 2 syndromes have different presentations.Aspiration pneumonia tends to occur in older patients or in those with neurological...
|
|
|
Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal
- One of the Largest Outcomes Trials In Coronary Intervention ACS Patients Will Evaluate Efficacy and Safety of Higher Loading and Initial Maintenance Doses of Plavix(R) - PARIS AND PRINCETON, N.J.--(BUSINESS WIRE)--Nov.6, 2008--Sanofi...
|
|
|
Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of
Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc.today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced...
|
|
|
Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal
- One of the Largest Outcomes Trials In Coronary Intervention ACS Patients Will Evaluate Efficacy and Safety of Higher Loading and Initial Maintenance Doses of Plavix(R) - PARIS AND PRINCETON, N.J.--(BUSINESS WIRE)--Sanofi-aventis (NYSE: SNY...
|
|
|
::: Publication in the American Heart Journal of CURRENT-OASIS 7 Trial Design
- CURRENT-OASIS 7 is one of the Largest Outcomes Trials Evaluating Higher Doses of Plavix in Patients with Acute Coronary Syndrome and undergoing Coronary Intervention - Paris, France and Princeton, New Jersey - November 6, 2008 - Sanofi...
|
|
|
Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results
Achieves Strongest Quarterly Revenue to Date at $26 Million and Ends Quarter with $520 Million in Cash, Excluding Recent Receipt of $20 Million Milestone Payment Raises Year-End Cash Guidance to Greater than $500 Million Advances ALN-TTR, an...
|
|
|
Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results
Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter of 2008 and company highlights. 'This past quarter has been largely focused on...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1, 2008 /PRNewswire-FirstCall/ -- Schering...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
/PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol designed to test ANA773 in both...
|
|
|
CNS Factors in Children May Predict MS
In an analysis of data from a retrospective study, investigators describe how MRI and CSF data can help predict which children develop MS after a first attack of inflammatory demyelination.Diagnosing multiple sclerosis (MS) in adults can...
|
|
|
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
SAN DIEGO, Oct.30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol...
|
|
|
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
SAN DIEGO, Oct.30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it has initiated dosing ANA773 in patients chronically infected with hepatitis C virus (HCV) in Part B of a two-part protocol designed to test...
|
|
|
Learn about the Animal Therapeutics and Diagnostics
-Reportlinker.com announces that a new market research report related to the Veterinary health industry is available in its catalogue.Animal Therapeutics and Diagnostics www.reportlinker.com/p096604/Animal-Therapeutics- and-Diagnostics...
|
|
|
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
/PRNewswire-FirstCall via COMTEX/ -- ANDS | Quote | Chart | News | PowerRating -- Anadys Pharmaceuticals, Inc.(Nasdaq: ANDS | Quote | Chart | News | PowerRating) announced today that it has initiated dosing ANA773 in patients chronically...
|
|
|
Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in
WASHINGTON, Oct.28 /PRNewswire-AsiaNet/ -- - Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for...
|
|
|
Gilead Announces Two-Year Clinical Data for Letairis (ambrisentan) for the Treatment of Pulmonary Arterial Hyp
- Gilead Sciences, Inc.(Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis(R) in patients with pulmonary arterial hypertension (PAH) (WHO Group 1). Data from...
|
|
|
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial
PHILADELPHIA-- (BUSINESS WIRE) -- Gilead Sciences, Inc.(Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis in patients with pulmonary arterial hypertension (PAH) ...
|
|
|
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Con
SAN FRANCISCO, Oct.27 (HSMN NewsFeed) -- Amgen (Nasdaq: AMGN ) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced that ENBREL is the first biologic with published clinical trial data to show sustained...
|
|
|
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial
- First Prospective Two-Year Safety and Efficacy Data to be Presented for an ERA Therapy in PAH - PHILADELPHIA--(BUSINESS WIRE)--Gilead Sciences, Inc.(Nasdaq:GILD - News) today announced results of a two-year (104-week), open-label,...
|
|
|
Enbrel (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Contin
/PRNewswire-FirstCall/ -- Amgen and Wyeth Pharmaceuticals, a division of Wyeth , today announced that ENBREL is the first biologic with published clinical trial data to show sustained improvements in multiple measures of efficacy in moderate...
|
|
|
Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Con
SAN FRANCISCO, Oct.27 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) , today announced that ENBREL is the first biologic with published clinical trial data to show sustained...
|
